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Glutamatergic neurons located in the hippo-
campus and the frontal, temporal, and parietal 
cortices are severely affected in Alzheimer’s dis-
ease (AD) patients (Braak and Braak, 1998; 
Francis, 2003). A study investigating changes in 
the glutamatergic system in AD brains indicates 
that cognitive deficits are more significantly cor-
related with reduced glutamatergic presynaptic 
bouton density than with neurofibrillary tangles 
or amyloid  burden (Bell et al., 2007). Defi-
ciencies in many stages of the glutamate cycle, 
including reduced glutamate uptake function, 
have been reported in AD and are correlated 
with cognitive decline (Masliah et al., 1996; 
Kirvell et al., 2006; Jacob et al., 2007; Kashani 
et al., 2008; Scott et al., 2011; Sokolow et al., 
2012). Reduced glutamate uptake function can 
lead to increased extracellular glutamate levels, 
which, after long periods of time, can potentially 
increase amyloid  production, as shown in pre-
vious studies (Lesné et al., 2005; Bordji et al., 
2010; Kim et al., 2010). Amyloid  has been 
reported to further induce glutamate release 
(Chin et al., 2007; Kabogo et al., 2010; Talantova 
et al., 2013), thus exacerbating glutamate levels. 
Moreover, amyloid  has been demonstrated 
to inhibit induction of long-term potentiation 
(LTP) and promote long-term depression (Wang 
et al., 2004; Li et al., 2009, 2011; Shankar et al., 
2008). This amyloid –facilitated long-term 
depression can be prevented by an extracellular 
glutamate scavenger (Li et al., 2009). Current lit-
erature suggests that homeostatic regulation of 
extracellular glutamate levels may play a crucial 
role in the pathogenesis of AD.
CORRESPONDENCE  
Chien-Liang Glenn Lin:  
lin.492@osu.edu
Abbreviations used: AD, Alz-
heimer’s disease; DHK, dihydro-
kainic acid; LTP, long-term 
potentiation; PMV, plasma 
membrane vesicle.
*K. Takahashi and Q. Kong contributed equally to this paper.
Restored glial glutamate transporter EAAT2 
function as a potential therapeutic approach 
for Alzheimer’s disease
Kou Takahashi,1* Qiongman Kong,1* Yuchen Lin,1 Nathan Stouffer,1 
Delanie A. Schulte,1 Liching Lai,1 Qibing Liu,1 Ling-Chu Chang,1  
Sky Dominguez,1 Xuechao Xing,2 Gregory D. Cuny,2,3 Kevin J. Hodgetts,2 
Marcie A. Glicksman,2 and Chien-Liang Glenn Lin1
1Department of Neuroscience, The Ohio State University, Columbus, OH 43210
2Laboratory for Drug Discovery in Neurodegeneration, Harvard NeuroDiscovery Center, Brigham and Women’s Hospital  
and Harvard Medical School, Boston, MA 02115
3Department of Pharmacological and Pharmaceutical Sciences, University of Houston College of Pharmacy, Houston,  
TX 77004
Glutamatergic systems play a critical role in cognitive functions and are known to be 
defective in Alzheimer’s disease (AD) patients. Previous literature has indicated that glial 
glutamate transporter EAAT2 plays an essential role in cognitive functions and that loss of 
EAAT2 protein is a common phenomenon observed in AD patients and animal models. In the 
current study, we investigated whether restored EAAT2 protein and function could benefit 
cognitive functions and pathology in APPSw,Ind mice, an animal model of AD. A transgenic 
mouse approach via crossing EAAT2 transgenic mice with APPSw,Ind. mice and a pharmaco-
logical approach using a novel EAAT2 translational activator, LDN/OSU-0212320, were 
conducted. Findings from both approaches demonstrated that restored EAAT2 protein 
function significantly improved cognitive functions, restored synaptic integrity, and reduced 
amyloid plaques. Importantly, the observed benefits were sustained one month after com-
pound treatment cessation, suggesting that EAAT2 is a potential disease modifier with 
therapeutic potential for AD.
© 2015 Takahashi et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/ 
by-nc-sa/3.0/).
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to distinguish EAAT2-mediated glutamate uptake from uptake 
mediated by the other EAATs. Results showed that total Na+-
dependent [3H]glutamate uptake activity (fmol/mg protein/
min) was decreased 12% in treated nontransgenic cultures 
(A: 175.9 ± 17.64 vs. +A: 156.5 ± 19.81) and not de-
creased in treated transgenic cultures (A: 257.4 ± 10.16 vs. 
+A: 258.0 ± 9.90; Fig. 1 B, left; and Table S1). The DHK- 
sensitive [3H]glutamate uptake activity (fmol/mg protein/min) 
was decreased 60% in treated nontransgenic cultures (A: 
33.8 ± 1.99 vs. +A: 12.6 ± 2.49) and 16% in treated 
transgenic cultures (A: 42.8 ± 3.88 vs. +A: 35.8 ± 1.76; 
Fig. 1 B, right; and Table S1). To evaluate the effects of increased 
EAAT2 on A25-35-induced neuronal toxicity, we visualized 
neuronal morphology by immunostaining with MAP2 anti-
bodies. Profound neuronal damage, specifically neurite degen-
eration, was observed in A25-35-treated nontransgenic cultures, 
whereas neurons in EAAT2 transgenic cultures were spared 
(representative images shown in Fig. 1 C). Importantly, the 
observed protective effects were abolished in the presence of 
DHK, indicating that the effects were caused by increased 
EAAT2 function (Fig. 1 C). DHK treatment alone did not 
cause neuronal damage as assessed by neuronal morphology, 
neuronal number, and number of dying neurons in the form of 
condensed nuclei (not depicted). To further quantify our obser-
vations, we counted the number of MAP2-positive neurons 
and found that A25-35 treatment did not decrease neuronal 
number in both transgenic cultures (547 neurons/2.2 mm2  
without A vs. 555 neurons/2.2 mm2 with A, averaged 
across four experiments) and nontransgenic cultures (535 neurons/ 
2.2 mm2 without A vs. 550 neurons/2.2 mm2 with A, 
averaged across five experiments). After, we counted MAP2-
positive neurons with condensed nuclei stained by Hoechst 
33342. The results showed that A25-35 treatment increased the 
number of neurons with condensed nuclei by 36% in non-
transgenic cultures but only 6% in transgenic cultures. Signifi-
cantly, when DHK was used to block EAAT2 function, the 
number of neurons with condensed nuclei in treated transgenic 
cultures increased by 39%, as observed in nontransgenic cul-
tures (Fig. 1 D). Furthermore, we quantified the intensity of 
MAP2 immunoreactivity as an indicator of neurite degenera-
tion and found that A25-35 treatment decreased MAP2 immuno-
reactivity by 30% in nontransgenic cultures but only 5% in 
transgenic cultures (Fig. 1 E). In the presence of DHK, MAP2 
immunoreactivity was significantly decreased by 33% in A25-35-
treated transgenic cultures, as observed in nontransgenic cul-
tures. These results indicate that increased EAAT2 expression 
and function protects against A25-35-induced neuronal damage 
in the presented in vitro culture model.
EAAT2 protein was restored in APPSw,Ind-crossed EAAT2 mice
To determine whether the observed protective effects in pri-
mary cultures are present in an AD animal model, we crossed 
our EAAT2 mice with APPSw,Ind mice to increase EAAT2 
protein expression levels. We previously reported that APPSw,Ind 
mice, at the age of 9 mo, when disease and pathology are evi-
dent, exhibited an 40% loss of EAAT2 protein expression as 
Excitatory amino acid transporter 2 (EAAT2) plays a crit-
ical role in the maintenance of low extracellular glutamate 
levels. EAAT2 is primarily localized in perisynaptic processes 
of astrocytes closely associated with excitatory synaptic con-
tacts (Chaudhry et al., 1995; Rothstein et al., 1996; Lin et al., 
2012). Previous literature has indicated that loss of EAAT2 
protein and function are commonly found in AD patients 
(Masliah et al., 1996; Jacob et al., 2007; Scott et al., 2011) and 
are an early event in disease pathology. Although the mecha-
nisms underlying the loss of EAAT2 remain unclear, a previ-
ous study has demonstrated that this loss is probably caused by 
disturbances at the posttranscriptional level because EAAT2 
mRNA is not decreased (Li et al., 1997). To determine 
whether the loss of EAAT2 contributes to AD, Mookherjee 
et al. (2011) crossed mice lacking one allele for EAAT2 with 
APPswe/PS1E9 mice and found accelerated cognitive 
deficits in the crossed mice. These findings suggest that de-
creased EAAT2 levels may contribute to AD.
In the present study, we aimed to investigate whether re-
stored EAAT2 protein levels and function could ameliorate 
AD-like behavior and pathology in mice and whether EAAT2 
is a potential therapeutic target for AD. These aims were as-
sessed using transgenic mice and pharmacological approaches. 
First, EAAT2 transgenic mice having a 1.5–2-fold increase in 
EAAT2 protein levels (Guo et al., 2003) were crossed with 
APPSw,Ind mice (Mucke et al., 2000). The crossed mice exhib-
ited restored EAAT2 protein levels and function and, most 
importantly, significantly improved cognitive functions, re-
stored synaptic integrity, and reduced amyloid plaques. Next, 
APPSw,Ind mice were treated with a novel brain-penetrant 
small molecule, LDN/OSU-0212320, which we previously 
identified as capable of increasing EAAT2 expression through 
translational activation (Colton et al., 2010; Xing et al., 2011; 
Kong et al., 2014). Significantly, we found that this compound 
can restore EAAT2 function and ameliorate AD-like behavior 
and pathology, thus having therapeutic potential for AD.
RESULTS
Increased EAAT2 protects against A-induced  
neuronal damage in primary cultures
As a first step, we investigated whether increased EAAT2 pro-
tein expression could prevent A25-35 oligomer–induced neu-
ronal toxicity in primary neuron and astrocyte mixed cultures. 
Cultures were prepared from EAAT2 transgenic pups that ex-
pressed 1.5–2-fold more EAAT2 than their nontransgenic 
WT littermates (Guo et al., 2003). 7-d-old cultures were treated 
with 40 µM A25-35 oligomers, and at 24 h, EAAT2 protein 
levels were determined by Western blot analysis. Results showed 
about a 45% decrease in EAAT2 protein levels in A-treated 
nontransgenic cultures and only about a 5.3% decrease in 
treated EAAT2 transgenic cultures (Fig. 1 A). It is notable that 
data can only be compared between treated and nontreated 
cultures prepared from the same pup brain; i.e., nontransgenic 
cultures cannot be compared with transgenic cultures. We also 
measured glutamate uptake activities by [3H]glutamate uptake 
assay. Dihydrokainic acid (DHK), an EAAT2 blocker, was used 
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Figure 1. Increased EAAT2 expression significantly protected against A25-35-induced neuronal damage in primary cultures. Cortical primary 
neuron and astrocyte mixed cultures were prepared from EAAT2 transgenic or WT pup littermates. 7-d-old primary cultures were treated with 40 µM 
A25-35 for 24 h. (A) Quantitative analysis of EAAT2 protein levels in A25-35-treated and nontreated cultures by Western blotting. Representative Western 
blot result is shown. EAAT2 signal intensity was normalized to its actin signal intensity on the same blot. It is notable that data can only be compared 
between treated and nontreated cultures prepared from the same pup brains (n = 4). (B) Glutamate uptake analysis. Left panel is total [3H]glutamate up-
take, and right panel is DHK-sensitive [3H]glutamate uptake (n = 4–5; ***, P < 0.001, Student’s t test). Raw data are presented in Table S1. (C) Representa-
tive images of immunocytochemistry staining with MAP2 and Hoechst 33342 showing neurite degeneration and nuclear condensation. The neurons 
indicated with arrows are magnified in the images on the right. The nuclear staining is represented in the insets. Bar, 50 µm. (D) Quantitative analysis of 
the number of neurons showing condensed nuclei. Approximately 500 neurons per culture were evaluated as the percentage of neurons showing con-
densed nuclei, and four to five cultures per group were statistically analyzed (*, P < 0.05, one way ANOVA followed by Holm-Šídák method). (E) Quantita-
tive analysis of MAP2 immunoreactivity. A total of 2.2-mm2 area per culture was evaluated, and the mean intensity of no treatment samples was 
arbitrarily set as 100%. Four to five cultures per group were statistically analyzed (*, P < 0.05, one way ANOVA followed by Holm-Šídák method). All data 
are from three independent experiments. Mean ± SEM is shown.
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epileptiform activity, and an abnormally high rate of premature 
death (Hsiao et al., 1995; Palop et al., 2007; Minkeviciene et al., 
2009; Verret et al., 2012). AD patients also have a high incidence 
of seizures and epilepsy (Friedman et al., 2012). We monitored 
these phenomena in APPSw,Ind and APP/EAAT2 mice. We 
found that by the age of 100 d, APPSw,Ind and APP/EAAT2 
mice showed accelerated mortality compared with WT, with 
36% and 17% death rates, respectively (Fig. 3 A); APP/EAAT2 
mice exhibited significantly lowered premature death rates 
(P < 0.05, 2 test). No marked weight loss, malformations of 
the vital organs, or major internal bleeding were associated 
with premature death. Seizure activity was observed and could 
have contributed to the premature death rate.
Next, we examined cognitive functions at 12–14 mo of 
age. Y-maze tests were conducted to assess short-term mem-
ory. Results revealed that APP/EAAT2 mice exhibited signif-
icantly improved spontaneous alternations compared with 
their APPSw,Ind littermates (Fig. 3 B). T-maze was then con-
ducted to assess spatial learning memory. Results showed that 
APP/EAAT2 mice exhibited significantly better spatial learning 
memory ability than their APPSw,Ind littermates (Fig. 3 C). 
These results were not the result of side preference effects be-
cause side preference was controlled for in the procedure, as 
described in Materials and methods. To assess nonspatial long-
term memory, novel object recognition tests were performed. 
As found with the other cognitive tests, it was determined 
that APP/EAAT2 mice had significantly improved novel ob-
ject recognition memory as compared with their APPSw,Ind 
littermates (Fig. 3 D). Interestingly, there was a tendency for 
compared with their WT littermates (Tian et al., 2010). 
Crossed mice were evaluated for EAAT2 protein levels and 
glutamate uptake function at 3, 6, and 9 mo of age. As shown 
in Fig. 2 A, EAAT2 protein expression decreased with age in 
APPSw,Ind mice, whereas at 9 mo of age, EAAT2 protein levels 
in the APP/EAAT2 mice remained similar to that of the WT 
mice. Even at 12 mo of age, the APP/EAAT2 mice exhibited 
similar EAAT2 protein levels as their nontransgenic litter-
mates in the hippocampus area (Fig. 2 B). Consistent with 
EAAT2 protein expression, DHK-sensitive [3H]glutamate 
uptake function was restored in APP/EAAT2 mice at 9 mo 
(Fig. 2 C; WT: 80.5 ± 5.03, APP: 33.3 ± 3.36, APP/EAAT2: 
86.0 ± 5.57, and EAAT2: 120.6 ± 7.43 fmol/mg protein/
min). We measured EAAT2 mRNA levels by quantitative 
RT-PCR analysis and found that EAAT2 mRNA levels did 
not decrease in APPSw,Ind mice, suggesting that loss of EAAT2 
protein is not caused by decreased mRNA levels (Fig. 2 D). 
These observed phenomena are similar to that reported in 
AD patients (Li et al., 1997). It is notable that total APP pro-
tein expression was not different in APP/EAAT2 mice com-
pared with their APPSw,Ind littermates (not depicted).
Improved cognitive functions and reduced  
AD-like pathology in APP/EAAT2 mice
To assess the potential benefits of increased EAAT2 protein ex-
pression, we investigated cognitive functions and pathological 
changes in crossed mice compared with their APPSw,Ind litter-
mates. Previous literature has indicated that several lines of 
APP mice exhibit network hyperexcitability, spontaneous 
Figure 2. Functional EAAT2 protein was restored in APP/EAAT2 mice. (A) Quantitative analysis of EAAT2 protein levels in the forebrain of the 
indicated mice. EAAT2 protein levels for each sample were normalized to actin protein levels (n = 6; *, P < 0.05; **, P < 0.01, Student’s t test). Repre-
sentative Western blot analysis of EAAT2 protein levels at 9 mo of age is shown. (B) Representative images of EAAT2 immunofluorescent staining for  
12-mo-old mice in the hippocampal dentate gyrus region (n = 3). Bar, 50 µm. (C) DHK-sensitive [3H]glutamate uptake activity (n = 3; ***, P < 0.001, one 
way ANOVA followed by Holm-Šídák method). PMVs prepared from mouse forebrains were used for glutamate uptake measurement. (D) EAAT2 mRNA 
levels in the forebrain of the indicated mice measured by real-time RT-PCR analysis (n = 6). Data are from six (A and D) and three (B and C) independent 
experiments. Mean ± SEM is shown.
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Figure 3. APP/EAAT2 mice exhibited improved premature death rate, memory, and pathology compared with their APP littermates. (A) Sur-
vival curves were generated from 246 mice: 63 APP/EAAT2, 69 APPSw,Ind, 59 EAAT2, and 55 WT littermates. (B–D) Behavior tests were conducted in 12–14-
mo-old mice (n = 14–17 per group). (B) Y-maze tests assessing short-term memory (***, P < 0.001, one way ANOVA followed by Holm-Šídák method). The 
dotted line represents the point at which mice did not remember the previously visited arm. (C) T-maze tests assessing spatial learning memory (*, P < 
0.05, one-way repeated ANOVA followed by Student’s t tests). (D) Novel object recognition tests assessing long-term nonspatial memory (**, P < 0.01;  
***, P < 0.001, one way ANOVA followed by Holm-Šídák method). The dotted line represents the point at which mice did not remember the previous 
object. (E, left) Representative images of synaptophysin immunostaining in the CA3 region. The right micrographs show high-magnification images of 
the boxed areas in the left micrographs. (right) Quantitative analysis of synaptophysin immunoreactivity in the CA3a region indicated by the boxed areas 
(n = 3–5 mice per group; *, P < 0.05, Student’s t test). (F, left) Quantitative analysis of A immunostaining (n = 4–5 mice per group; *, P < 0.05; **, P <  
0.01, Student’s t test). (right) Representative images of A immunostaining in the dentate gyrus region are shown. Nuclei were stained with Hoechst 
33342 (blue). (E and F) Bars, 50 µm. Data are from six (A), four (B–D), and three (E and F) independent experiments. Mean ± SEM is shown.
324 Restored EAAT2 improves cognitive functions in AD | Takahashi et al.
images of the dentate gyrus region are shown in Fig. 3 F. 
These results suggest that restored EAAT2 protein function 
ameliorates amyloid deposition.
LDN/OSU-0212320 improved cognitive functions  
and reduced pathology in APPSw,Ind mice
The aforementioned transgenic mice studies indicated that 
restored EAAT2 protein function benefits APPSw,Ind mice. 
We then further investigated whether restored EAAT2 pro-
tein levels at symptomatic stages via a novel brain-penetrant 
compound, LDN/OSU-0212320 (Fig. 4 A), could provide 
therapeutic benefits in APPSw,Ind mice. As mentioned previ-
ously, loss of EAAT2 protein in APPSw,Ind mice is caused by 
disturbances at the posttranscriptional level because EAAT2 
mRNA is not decreased; LDN/OSU-0212320 is capable of 
increasing EAAT2 expression through translational activa-
tion. Several preliminary experiments were conducted. First, 
to determine the optimal compound dosage, we assessed 
three different doses (10, 20, and 30 mg/kg) in 12-mo-old 
APPSw,Ind mice. The results showed that EAAT2 protein lev-
els were restored to normal levels at the dosage of 30 mg/kg 
by i.p. injection after 3-d daily treatment (Fig. 4 B). Second, 
although we have previously demonstrated the safety of this 
compound (Kong et al., 2014), we reconfirmed that long-
term daily compound treatment at 30 mg/kg for 2 mo in 
APPSw,Ind mice did not cause any abnormal behavior or body 
weight loss. Third, to determine an appropriate treatment 
Figure 4. EAAT2 protein levels were restored by LDN/
OSU-0212320 in 12-mo-old APPSw,Ind mice. (A) Struc-
ture of LDN/OSU-0212320. (B) 12-mo-old APPSw,Ind mice 
were treated with the indicated dosages of compound by 
i.p. injection for 3 d. PMVs were prepared from forebrains 
to determine EAAT2 protein levels by Western blot analysis. 
EAAT2 signal intensity was normalized to its actin signal 
intensity on the same blot (n = 3; *, P < 0.05; **, P < 0.01, 
one way ANOVA followed by Holm-Šídák method). Repre-
sentative Western blots are presented. (C) Mice were 
treated with 30 mg/kg LDN/OSU-0212320 i.p. for 2 mo 
starting at 12 mo of age and were subjected to behavior 
tests (results shown in Fig. 6). After all behavior tests, PMVs 
were prepared from forebrains to determine EAAT2 protein 
levels by Western blot analysis. EAAT2 signal intensity was 
normalized to its actin signal intensity on the same blot 
(n = 3–4; *, P < 0.05, Student’s t test). Representative 
Western blots are presented. All data are from three inde-
pendent experiments. Mean ± SEM is shown.
EAAT2 mice to show better cognitive functions in these 
behavior tests compared with their WT littermates. Conclu-
sively, these cognitive assessments indicate that restored EAAT2 
protein function benefits cognitive functions.
To determine whether these cognitive-behavioral im-
provements were accompanied by restored synaptic integrity, 
we performed immunohistochemistry with synaptophysin 
antibodies. Synaptophysin is a presynaptic protein that has 
been widely used as a synaptic marker (Honer, 2003). Con-
sistent with previous studies (Hsia et al., 1999; Mucke et al., 
2000), a decrease in hippocampal synaptophysin immuno-
reactivity was observed in APPSw,Ind mice. However, APP/
EAAT2 mice exhibited restored synaptophysin immuno-
reactivity (representative images are shown in Fig. 3 E). 
Quantitative analysis of the CA3a region, which consists of 
mossy fiber terminals projected from the dentate gyrus and plays 
an important role in the encoding of new spatial information, 
indicated that APP/EAAT2 mice exhibit significantly higher 
synaptophysin immunoreactivity than APP mice (Fig. 3 E).
Furthermore, we examined amyloid deposition in young 
(6–9 mo) and older (12–15 mo) mice. Consistent with a pre-
vious study (Mucke et al., 2000), age-dependent A plaque 
formation was detected in APPSw,Ind mice by immunostaining 
with 6E10 antibodies. Fig. 3 F shows the quantitative results 
of the hippocampus regions, including CA1, CA3, and den-
tate gyrus, in older mice (12–15 mo). APP/EAAT2 mice ex-
hibited significantly lowered plaque burden compared with 
their APPSw,Ind littermates in all three regions. Representative 
JEM Vol. 212, No. 3
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progress at 7 mo. From these preliminary experiments, we 
determined that compound treatment starting at 7 mo and at 
30 mg/kg would be most appropriate.
time, we evaluated cognitive functions by Y-maze, T-maze, 
and novel object recognition tests at 5 and 7 mo. Cognitive 
declines were already present by 5 mo and continued to 
Figure 5. LDN/OSU-0212320–ameliorated memory deficits and pathology in 7-mo-old APPSw,Ind mice. Mice were treated with 30 mg/kg LDN/
OSU-0212320 i.p. starting at 7 mo of age. After 10 d of treatment, mice were subjected to Y-maze test, which was repeated after 30 d of treatment. After 
60 d of treatment, mice underwent three cognitive tests (n = 18–24 per group) and then pathological experiments (n = 4 per group). (A) Y-maze tests 
assessing short-term memory (*, P < 0.05; **, P < 0.01; ***, P < 0.001, one way ANOVA followed by Holm-Šídák method). The dotted line represents the 
point at which mice did not remember the previously visited arm. (B) T-maze tests assessing spatial learning memory (*, P < 0.05, one-way repeated 
ANOVA followed by Student’s t tests). (C) Novel object recognition tests assessing long-term nonspatial memory (**, P < 0.01; ***, P < 0.001, one way 
ANOVA followed by Holm-Šídák method). The dotted line represents the point at which mice did not remember the previous object. (D, left) Representa-
tive images of synaptophysin immunostaining in the CA3 region. The right micrographs show high-magnification images of the boxed areas in the left 
micrographs. (right) Quantitative analysis of synaptophysin immunoreactivity in the CA3a region indicated by the boxed areas (*, P < 0.05, Student’s  
t test). (E, left) Quantitative analysis of A immunostaining (*, P < 0.05, Student’s t test). (right) Representative images of A immunostaining in the den-
tate gyrus region are shown. Nuclei were stained with Hoechst 33342 (blue). (D and E) Bars, 50 µm. Data are from six (A–C) and three (D and E) indepen-
dent experiments. Mean ± SEM is shown.
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immunostaining, was observed in the hippocampal CA3 
region of compound-treated APPSw,Ind mice but not in their 
APPSw,Ind littermates treated with vehicle. Quantitative analysis 
of the CA3a region confirmed that compound-treated APPSw,Ind 
mice exhibited significantly restored synaptophysin immuno-
reactivity (Fig. 5 D). Amyloid deposition was assessed by 6E10 
antibodies. Results showed significantly lowered plaque burden 
in the hippocampal dentate gyrus as well as in the CA1 and 
CA3 subregions in compound-treated APPSw,Ind mice as com-
pared with APPSw,Ind littermates treated with vehicle (Fig. 5 E).
To further investigate whether our compound could still 
provide benefits in older APPSw,Ind mice, we performed simi-
lar behavioral and pathological experiments with compound 
treatment starting in 12-mo-old mice. Fig. 6 presents our 
findings, which were similar to the results we found in 7-mo-
old mice. Specifically, compound-treated mice exhibited 
better cognitive functions across the Y-maze, T-maze, and 
novel object recognition tests (Fig. 6, A–C); additionally, it 
restored synaptic integrity (Fig. 6 D) and slightly reduced 
amyloid deposition in the dentate gyrus, but not in CA1 and 
CA3 subregions (Fig. 6 E). After all behavior tests, EAAT2 
protein levels were measured, and the results showed that 
EAAT2 levels were restored in compound-treated mice 
(Fig. 4 C). Collectively, these behavioral and pathological 
findings indicate that LDN/OSU-0212320, which is capable 
of restoring EAAT2 protein levels, may serve as a potential 
therapeutic avenue.
Littermate-matched mice were divided into four groups: 
compound-treated APPSw,Ind, vehicle-treated APPSw,Ind, 
compound-treated WT, and vehicle-treated WT mice. Each 
group contained 18–24 mice with similar gender distribution. 
Mice were treated at the same time every day, starting at 7 mo, 
with 30 mg/kg of compound by i.p. injection. After 10 d of 
treatment, mice were subjected to short-term memory assess-
ment by Y-maze, which was repeated after 30 d of treatment. 
After 60 d of treatment, mice underwent three cognitive tests, 
including Y-maze, T-maze, and novel object recognition tests. 
Examiners were blinded regarding treatment. After the behav-
ioral test, mice were euthanized for pathological studies.
The results are presented in Fig. 5. Y-maze results demon-
strated that short-term memory was restored after 10 d and 
continued to improve at 30 and 60 d after compound treat-
ment (Fig. 5 A). T-maze results showed that spatial learning 
memory significantly improved after 60 d of treatment (Fig. 5 B). 
Novel object recognition test results also revealed signifi-
cantly restored nonspatial long-term memory (Fig. 5 C). No-
tably, there were no obvious differences in compound effects 
between genders. In addition, we found that compound-
treated WT mice exhibited better cognitive functions com-
pared with that of their vehicle-treated littermates, and these 
findings were consistent with those observed in transgenic 
mice (Fig. 3).
Follow-up pathological experiments found that an in-
crease in synaptophysin immunoreactivity, as assessed by 
Figure 6. LDN/OSU-0212320–ameliorated memory deficits and pathology in 12-mo-old APPSw,Ind mice. Mice were treated with 30 mg/kg LDN/
OSU-0212320 i.p. starting at 12 mo of age. After 10 d of treatment, mice were subjected to Y-maze test, which was repeated after 30 d of treatment. 
After 60 d of treatment, mice underwent three cognitive tests (n = 18–21 per group) and then pathological experiments (n = 4 per group). (A) Y-maze 
tests assessing short-term memory (**, P < 0.01, one way ANOVA followed by Holm-Šídák method). The dotted line represents the point at which mice did 
not remember the previously visited arm. (B) T-maze tests assessing spatial learning memory (*, P < 0.05; **, P < 0.01, one-way repeated ANOVA followed 
by Student’s t tests). (C) Novel object recognition tests assessing long-term nonspatial memory (***, P < 0.001, one way ANOVA followed by Holm-Šídák 
method). The dotted line represents the point at which mice did not remember the previous object. (D) Quantitative analysis of synaptophysin immuno-
staining in the CA3a region (**, P < 0.01, Student’s t test). (E) Quantitative analysis of A immunostaining (**, P < 0.01, Student’s t test). Data are from 
four (A–C) and three (D and E) independent experiments. Mean ± SEM is shown.
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nontransgenic cultures, but not in transgenic cultures. Previous 
literature has demonstrated that A can cause glutamate re-
lease, leading to excess glutamate-mediated neuronal damage, 
including synaptic loss (Chin et al., 2007; Kabogo et al., 2010; 
Talantova et al., 2013). Loss of synapses may make glutamate 
uptake unnecessary, thus down-regulating EAAT2. In EAAT2 
transgenic cultures, increased EAAT2 levels can prevent excess 
glutamate-mediated toxicity and thus preserve synaptic integ-
rity and EAAT2 protein levels. The cultures contained neurons 
that express EAAT3, type 1 astrocytes that express EAAT1, 
and type II astrocytes that express EAAT2. The population of 
type 1 astrocytes (EAAT1) in cultures is much higher than that 
of type 2 astrocytes (EAAT2). This is because differentiated 
type 2 astrocytes are not divided, but type 1 astrocytes continue 
dividing. The numbers of type 2 astrocytes are correlated with 
the numbers of neurons. Therefore, only 20% of glutamate 
uptake is inhibited by DHK. These cultures are appropriate for 
this study because they contain both neurons and type 2 astro-
cytes, which allowed us, as a first step, to assess whether in-
creased EAAT2 protein expression could prevent A-induced 
neuronal toxicity in vitro. The positive results from these ex-
periments (Fig. 1) led us to move on with the in vivo trans-
genic mice and compound experiments (Figs. 2–7). We have 
previously used the primary neuron and astrocyte mixed cul-
tures to demonstrate the protective effects of increased EAAT2 
expression in glutamate-mediated toxicity in our EAAT2 
transgenic mice study (Guo et al., 2003) and also in our com-
pound LDN/OSU-0212320 study (Kong et al., 2014).
Beneficial effects of LDN/OSU-0212320  
are sustained after 1-mo treatment cessation
To evaluate how long the benefits of treatment could last, 
12-mo-old APPSw,Ind mice were treated with LDN/OSU-
0212320 for 2 mo and assessed for cognitive functions and 
pathology 1 mo after treatment was ceased. Y-maze assess-
ment was measured 10, 20, and 30 d after treatment cessation 
and revealed sustained improved spatial short-term memory 
(Fig. 7 A). Improved spatial learning memory (T-maze test) 
and nonspatial long-term memory (novel object recognition 
test) were sustained 30 d after treatment was ceased, with 
gradual decline over time (Fig. 7, B and C). Consistently, 
synaptic integrity was also maintained 30 d after treatment 
(Fig. 7 D). However, amyloid deposition was not different 
between the two groups (Fig. 7 E). EAAT2 protein levels in 
compound-treated APPSw,Ind mice returned to similar levels 
as that in APPSw,Ind vehicle-treated mice in the absence of 
compound (not depicted). These results suggest that the ob-
served beneficial effects are not palliative and that EAAT2 is 
a potential disease modifier for AD.
DISCUSSION
In the present study, we found that restored EAAT2 protein 
function attenuated premature death, memory loss, and AD-like 
pathology in APPSw,Ind mice. These findings were solidly con-
firmed via a transgenic mouse and pharmacological approaches.
In our primary culture experiments (Fig. 1), we found that 
A25-35 caused severe neuronal damage and loss of EAAT2 in 
Figure 7. The beneficial effects of LDN/OSU-0212320 were sustained 1 mo after treatment was ceased. 12-mo-old mice were treated with  
30 mg/kg LDN/OSU-0212320 i.p. for 2 mo and subjected to behavior tests (n = 10–11 mice per group) and pathological experiments (n = 4 mice per 
group) 1 mo after treatment cessation. (A) Y-maze assessment was measured 10, 20, and 30 d after treatment cessation (*, P < 0.05; **, P < 0.01, one way 
ANOVA followed by Holm-Šídák method). The dotted line represents the point at which mice did not remember the previously visited arm. (B) T-maze 
tests (*, P < 0.05; **, P < 0.01, one-way repeated ANOVA followed by Student’s t tests). (C) Novel object recognition tests (*, P < 0.05; ***, P < 0.001, one 
way ANOVA followed by Holm-Šídák method). The dotted line represents the point at which mice did not remember the previous object. (D) Quantitative 
analysis of synaptophysin immunostaining in the CA3a region (*, P < 0.05, Student’s t test). (E) Quantitative analysis of A immunostaining. Data are 
from four (A–C) and three (D and E) independent experiments. Mean ± SEM is shown.
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that EphA4/ephrin-A3 signaling is a critical mechanism for 
astrocytes to regulate synaptic function and plasticity. More-
over, Verbich et al. (2012) reported that EAAT2-mediated 
glutamate transport modulates dendritic spine head protru-
sions in the hippocampus and suggested that EAAT2 control of 
extracellular glutamate is important for spine head protrusion–
mediated plasticity of spines. Based on our findings, we spec-
ulate that amyloid –induced synaptic loss/dysfunction may 
lead to down-regulated EAAT2 protein expression at the 
translational level. Reactivating EAAT2 translation via LDN/
OSU-0212320 restores synaptic plasticity and function, pos-
sibly through the EphA4/ephrin-A3 signaling pathway; this 
may account for the observed restored memory and learning 
functions in our compound-treated mice. This potential 
mechanism is currently under investigation.
Our data suggest that restored EAAT2 function is a po-
tential new therapeutic approach for AD. Currently, clinical 
studies have focused on drugs that target the amyloid cascade. 
However, results from these studies have not yet yielded 
promising outcomes (Salomone et al., 2012; Tayeb et al., 
2012). Our approach has several demonstrated advantages 
using LDN/OSU-0212320: (a) reverses memory and learn-
ing deficits after a short period of treatment, (b) sustains ben-
eficial effects on cognitive functions even after 1 mo of 
treatment cessation, indicating a potential for disease modifi-
cation, (c) restores synaptic integrity, and (d) increases EAAT2 
expression via the translational rather than the transcriptional 
activation mechanism, which resolves the central problem of 
reduced EAAT2 expression. LDN/OSU-0212320 or its de-
rivatives may have therapeutic potential for AD. Continued 
development of this compound series is currently under way.
MATERIALS AND METHODS
Animals. EAAT2 transgenic mice from a FVB/N mouse strain were pre-
viously generated in our laboratory (Guo et al., 2003). The EAAT2 trans-
gene is driven by the human glial fibrillary acidic protein promoter. APPSw,Ind 
transgenic mice ( J20 mice, C57BL/6 mouse strain) were obtained from 
the laboratory of L. Mucke (The J. David Gladstone Institutes of San Fran-
cisco, San Francisco, CA). The APP/EAAT2 transgenic line was maintained 
by mating APPSw,Ind males with EAAT2 females. Transgenes were deter-
mined by PCR using genomic DNA extracted from tail biopsies at 3 wk 
old with EAAT2 transgene–specific primers (5-GGCAACTGGGGATG-
TACA-3 and 5-ACGCTGGGGAGTTTATTCAAGAAT-3) and APP 
transgene–specific primers (5-GGTGAGTTTGTAAGTGATGCC-3 and 
5-TCTTCTTCTTCCACCTCAGC-3). PCR conditions were as follows: 
for EAAT2, 94°C for 3 min, 94°C for 30 s, 55°C for 30 s, 72°C for 2 min 
for 30 cycles, followed by a 10-min extension at 72°C; for APP, 94°C for 
90 s, 94°C for 30 s, 60°C for 45 s, 72°C for 45 s for 30 cycles, followed by 
2-min extension at 72°C. Mice were housed in a 12-h light/dark cycle with 
free access to food and water. For compound treatment, mice received i.p. 
administration of LDN/OSU-0212320 at the indicated doses in 500 µl of 1% 
DMSO/1% polyethylene glycol 400/0.2% Tween 80/10% hydroxypropyl--
cyclodextrin/saline. All experiments were approved by the Institutional Ani-
mal Care and Use Committee of The Ohio State University and the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals.
Primary neuron and astrocyte mixed culture experiments. Primary dis-
sociated neuron and astrocyte mixed cultures were prepared from the cortical 
brain of newborn (12–24 h) EAAT2 transgenic and nontransgenic pups as previ-
ously described (Guo et al., 2003). These cultures were maintained in DMEM 
In our APP crossed EAAT2 mice experiments (Fig. 3), we 
found that APP/EAAT2 mice had significantly lowered pre-
mature death rates as compared with their APP littermates. 
This is probably caused by increased EAAT2 decreasing hyper-
excitability. This possibility is currently under investigation. It 
is notable that we previously observed that increased EAAT2 
protein expression provides significantly reduced seizure activ-
ity, neuronal death, and mortality rate in a pilocarpine-induced 
epilepsy model (Kong et al., 2012, 2014).
Furthermore, we found that APP/EAAT2 mice exhibited 
significantly improved cognitive functions and attenuated 
pathological changes. These beneficial effects are probably 
caused by reduced A-mediated glutamate toxicity but not 
A deposition. Notably, we found that increased EAAT2 was 
not able to decrease A deposition in older mice as effectively 
as in younger mice (Figs. 5 E and 6 E). This suggests that 
EAAT2 may help prevent A formation but cannot as ade-
quately degrade preexisting A deposition in older mice. Ad-
ditionally, it was found that A deposition does not contribute 
to restored memory (Fig. 7), suggesting that restored synapse 
integrity serves as a major player in memory restoration. Fur-
thermore, we found that LDN/OSU-0212320 restored 
EAAT2 protein levels concomitant with improved synaptic 
integrity and cognitive functions. LDN/OSU-2123210 in-
creases EAAT2 expression through the translational activation 
mechanism (Kong et al., 2014). It is possible that EAAT2 pro-
tein levels in perisynaptic processes of astrocytes are depen-
dent on synaptic activity and are highly regulated at the 
translational level. Because synaptic plasticity is dynamic, 
translational regulation can more effectively respond to syn-
aptic changes. This may be the reason why EAAT2 mRNA 
levels did not change in APP mice, whereas EAAT2 protein 
was down-regulated at the disease stage when significant syn-
aptic loss occurred. Restoration of EAAT2 may prevent ex-
cess glutamate-mediated toxicity caused by A. Additionally, 
it is possible that restored EAAT2 protein can reversely acti-
vate silent synapses to become active synapses. The detailed 
underlying mechanisms are currently being investigated.
Previous literature has indicated that EAAT2 plays an es-
sential role in cognitive memory functions. As mentioned 
above, Mookherjee et al. (2011) reported accelerated cogni-
tive deficits in APPswe/PS1E9 mice as a consequence of 
EAAT2 protein loss. Bechtholt-Gompf et al. (2010) addi-
tionally reported that blocking EAAT2 glutamate uptake 
function by DHK impaired spatial memory. Furthermore, 
Pita-Almenar et al. (2012) reported increased glutamate up-
take in hippocampal slides during early and late LTP. They 
demonstrated that EAAT2 is responsible for the increase in 
glutamate uptake during late LTP and that it may play an on-
going role in hippocampal circuitry to code and store infor-
mation. Heo et al. (2012) also reported that increased EAAT2 
complex levels were linked to spatial memory training during 
multiple T-maze tests. On a molecular level, Filosa et al. 
(2009) and Carmona et al. (2009) both reported that 
neuron–glia communication via EphA4/ephrin-A3 modulates 
LTP through glial glutamate transport. The studies suggested 
JEM Vol. 212, No. 3
Article
329
Coulter). The amount of l-[3H]glutamate uptake was calculated from the scin-
tillation counting results using the following equation: [3H]glutamate uptake 
(nmol) = (counts per minute/efficiency)/(2.22 × 106 disintegrations per 
minute/µCi)/(specific activity). Na+-dependent l-[3H]glutamate uptake was cal-
culated by subtracting Na+-independent l-[3H]glutamate uptake (in Na+-free 
Krebs buffer) from the total l-[3H]glutamate uptake (in Na+-containing Krebs 
buffer). DHK-sensitive l-[3H]glutamate uptake was calculated by subtracting 
DHK-insensitive Na+-dependent l-[3H]glutamate uptake (DHK-treated sam-
ple) from total Na+-dependent l-[3H]glutamate uptake. The protein concen-
tration was determined by the Bradford assay (Thermo Fisher Scientific). 
l-[3H]glutamate uptake was represented as fmol/mg protein/min. Each value 
was made from the mean of triplicate data.
Y-maze test. The spontaneous alternation behavior of mice in a Y-maze 
was used to measure short-term memory deficits and motor activity in APP/
EAAT2 mice. The maze apparatus consisted of three identical arms (35 × 
5 × 10 cm) spaced at 120° apart and made of gray plastic. Each mouse was 
placed at the end of an arm and allowed to move freely throughout the maze 
during a 10-min session. An arm entry was recorded when a mouse moved 
all 4 ft into the arm. Motor activity was measured as the total number of arm 
entries. Short-term memory was measured as the percentage of spontaneous 
alternation. Alternation was defined as successive entries into the three arms 
on overlapping triplet sets. Spontaneous alternation (%) was calculated as the 
ratio of actual alternations to possible alternations, multiplied by 100, a 
method based on a previous study (Maurice et al., 1996).
T-maze test. To assess learning and memory deficits, the following proce-
dure was performed: mice were maintained on a diet of 85% ad lib body 
weight to make the milk reward more appealing, and water was readily 
available. T-maze consisted of a 27 cm × 23 cm start box and a 30 cm × 11 cm 
start arm leading to two identical goal arms of 30 cm × 11 cm surrounded 
by a wall 10 cm high. A 35-mm plastic food dish was located 3 cm 
from the end of each goal arm. The maze was located on a table 1 m above 
the floor surrounded by a black board. The mice were first habituated to the 
maze for 3 d (3 min per mouse) and then habituated to a milk reward (2 ml 
of 50% sweetened, condensed milk). Next, mice were run through the maze 
three to five times each to determine their side preferences. Mice that dem-
onstrated distinct side preferences only required three trials, whereas others 
required up to five trials. T-maze was measured for 9 d and consisted of four 
repeated trials with 60 min between trials. Mice were purposely trained 
against their side preferences with a milk reward in two steps: (1) a sample 
run in which the preferred side was blocked and the reward of 100 µl of 25% 
sweetened condensed milk was placed in the food dish at the end of the op-
posite arm and (2) a choice run in which the block was removed and mice 
were placed in the start arm with their backs facing the two choice arms and 
were free to choose the correct arm. The time interval between the sample 
and choice run was 5 s. Ideally, over time, the mice would learn to run to 
the arm containing the milk reward and learn against their side preferences. 
In the event that the mice went to the incorrect arm, the block was reapplied 
for 10 s, trapping the mice in the incorrect side without milk (as a form of 
punishment). Mice that directly and quickly went to the correct side con-
taining the milk reward received a score of 1, and incorrect responses re-
ceived a score of 0. The data are presented as the percentage of correct 
responses out of total number of responses. The examiner was blinded for 
genotype and treatment of mice.
Novel object recognition test. Novel object recognition tests based on the 
procedure of a previous study were performed, which consisted of a training 
phase and a testing phase (Stefanko et al., 2009). Mice were handled for at 
least 5 d to avoid stress, novelty of handling, and transport procedures. A plas-
tic rectangular open field (35 × 45 × 30 cm) was used in balanced low-light 
conditions. The procedure consisted of three different phases: a habituation 
phase, an acquisition phase, and a retention phase. Mice were habituated to 
the experimental apparatus 15 min a day for two consecutive days in the ab-
sence of objects. During the acquisition phase, mice were placed in the 
and supplemented with 0.5% fetal bovine serum, 100 µg/ml penicillin- 
streptomycin, and 1× B-27 (Invitrogen). 7-d-old cultures were used in this 
study. A25-35 (American Peptide) peptides were dissolved in water as previously 
described (Pike et al., 1993), and oligomers were confirmed as aggregate forms 
by Ponceau staining. 100 µM DHK (Sigma-Aldrich) was used to block EAAT2 
function and added to the cultures 30 min before addition of A25-35. After 24 h 
of treatment, cultures were harvested for analyses. EAAT2 protein levels and 
glutamate uptake experiments are described below. For analyzing neuron mor-
phology and number, cultures were fixed with 4% paraformaldehyde in 0.1 M 
PB (phosphate buffer), pH 7.4, permeabilized with 0.1% saponin in PBS for 
20 min, blocked with 1% BSA in PBS/0.1% saponin for 30 min, and incubated 
with mouse anti-MAP2 antibodies (1:500; NeoMarker) in PBS containing 1% 
BSA overnight at 4°C. After washing with PBS containing 0.1% saponin, cells 
were incubated with Alexa Fluoro secondary antibodies and 1 µg/ml Hoechst 
3342 (to visualize nuclear morphology) in PBS containing 1% BSA for 60 min, 
followed by thorough washing with PBS/0.1% saponin. Images were obtained 
using an Axioskop 2 upright microscope (Carl Zeiss) with AxioVision software 
(using Carl Zeiss 20×/0.5NA Plan-Neofluar). 15 fields (0.15 mm2/field) per 
well were analyzed to determine total number of neurons, number of neurons 
with condensed nuclei, and intensity of MAP2 immunoreactivity. Each experi-
ment was repeated three times. For MAP2 immunoreactivity, ImageJ 1.48b 
software (National Institutes of Health) was used to obtain the fluorescence in-
tensity. For each experiment, the mean of immunoreactivity intensity from 15 
fields of no A25-35 treatment (control) samples was arbitrarily set as 100%, and 
A25-35 treatment sample intensities were normalized to this control.
Immunoblot analysis. Immunoblotting was performed as described previ-
ously (Tian et al., 2010). In brief, the harvested samples from primary culture 
cells or plasma membrane vesicles (PMVs) prepared from forebrains were as-
sayed for protein concentration, resolved by SDS-PAGE (8% polyacrylamide 
gel), and transferred onto nitrocellulose membranes. The following primary 
antibodies were used: rabbit anti-EAAT2 polyclonal antibodies (against the 
C terminus; 1:200) and goat anti-actin polyclonal antibodies (1:2,000; Santa 
Cruz Biotechnology, Inc.). The immunoreactive bands were detected using 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scien-
tific) according to the manufacturer’s directions. Band intensities were 
analyzed using ImageJ software.
[3H]glutamate uptake assay. For primary culture experiments, we fol-
lowed the procedures as reported previously (Tian et al., 2010). In brief, cells 
grown on 24-well plates were washed with sample buffer (320 mM sucrose 
in 50 mM Tris HCl, pH 7.4) and then incubated with Na+-containing or 
Na+-free Krebs buffer, which contains 0.125 µCi l-[3H]glutamate (specific 
activity = 50.6 µCi/nmol; GE Healthcare) and 40 µM unlabeled glutamate, 
for 10 min at 37°C. Afterward, cells were washed with ice-cold 1× PBS and 
lysed in 1 mM NaOH. To distinguish DHK-sensitive [3H]glutamate uptake 
from DHK-insensitive uptake, samples were incubated with 300 µM DHK 
(Sigma-Aldrich) 30 min before uptake.
For measuring the uptake of [3H]glutamate into PMVs, we followed 
procedures as previously described (Guo et al., 2003). Mouse forebrain tis-
sues were homogenized in sample buffer using a Dounce homogenizer and 
then centrifuged at 1,000 g for 10 min at 4°C. The supernatant (S1) was then 
centrifuged at 20,000 g for 30 min at 4°C, and the resultant PMV pellet (P2) 
was resuspended in either Na+-containing or Na+-free Krebs buffer. 100 µg 
PMV protein sample was used in each assay. The samples were incubated in 
400 µl Na+-containing or Na+-free Krebs buffer, which contains 0.1 µCi 
l-[3H]glutamate and 10 µM unlabeled glutamate, for 4 min at 37°C and then 
rapidly chilled on ice. The samples were then centrifuged at 20,000 g for 
10 min at 4°C, and the pellets were rinsed with ice-cold 1× PBS and lysed 
in 1 mM NaOH. Each sample was measured three times. Three sets of mice 
were examined. To distinguish DHK-sensitive [3H]glutamate uptake from 
DHK-insensitive uptake, samples were incubated with 300 µM DHK 
(Sigma-Aldrich) 30 min before uptake.
The amount of radiolabeled glutamate was measured using an LS6500 
Multi-Purpose Scintillation Counter (counting efficiency for 3H = 68%; Beckman 
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for multiple group comparisons, data were analyzed by one-way ANOVAs 
and pairwise multiple comparisons by the Holm-Šídák method when data 
passed normality and equal variance tests. Immunostaining and glutamate 
uptake data were analyzed using two-tailed Student’s t tests or ANOVA fol-
lowed by Holm-Šídák method for data that passed normality and equal vari-
ance tests. The data were analyzed using Prism (GraphPad Software) or 
SigmaPlot. Values were considered significant at P < 0.05.
Online supplemental material. Table S1 shows glutamate uptake raw 
data. Online supplemental material is available at http://www.jem.org/cgi/ 
content/full/jem.20140413/DC1.
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experimental apparatus with two identical objects (toy A & A; 4 × 5 × 3 cm) 
and were allowed to explore for 10 min. The location of the object was 
counterbalanced. The objects and apparatus were thoroughly cleaned be-
tween trials to ensure that olfactory cues were not present. Retention was 
tested 24 h for long-term memory. During the retention phase, mice ex-
plored the experimental apparatus for 10 min in the presence of a familiar 
(toy A) and a novel object (toy B; 4 × 4 × 4 cm). Toy B was a distinct object 
with comparable manipulability and complexity made of the same type of 
material as toy A, and it was preapproved to have comparable attractiveness to 
another cohort of WT mice from the same strain. To determine the number 
of times that the mouse had visited the novel and familiar objects, all acqui-
sition and retention trials were videotaped and analyzed independently by 
two individuals blind to treatment conditions and the genotype of subjects. 
A mouse was scored as exploring an object when its head was oriented toward 
the object within a distance of 1 cm or upon nose contact. Nnovel refers to the 
total times that mice approached the novel object (toy B), and Nfamiliar refers 
to the total times that mice approached toy A. The novel object recognition 
of toy B was expressed by [B% = Nnovel/(Nnovel + Nfamiliar) × 100%].
Immunohistochemistry. Mice were perfused transcardially with 4% para-
formaldehyde in 0.1 M PB after being deeply anesthetized with 200 µl/10 g 
i.p. tribromoethanol (Avertin). Brains were rapidly dissected and stored in 4% 
paraformaldehyde for postfixation for 24 h, followed by cryoprotection with 
30% sucrose for 72 h. 25-µm-thick coronal sections (1.7 to 2.7 mm from 
Bregma for hippocampal analysis) were cut with a Microm cryostat at 20°C. 
Free floating brain sections were blocked in 5% normal goat serum (NGS; 
Vector Laboratories) with 0.2% Triton X-100 in Tris-buffered saline (TBS) 
for 60 min and incubated in specific antibodies overnight at 4°C. After thor-
ough washing with TBS, sections were incubated with goat anti–rabbit or 
anti–mouse Alexa Fluoro secondary antibodies in TBST containing 2% NGS 
for 60 min, followed by thorough washing with TBS. The following anti-
bodies were used: rabbit EAAT2 (1:200), mouse 6E10 (1:100; Covance), and 
mouse synaptophysin (1:1,000; EMD Millipore). Sections were washed thor-
oughly, mounted on glass slides, and cover-slipped with Immu-Mount 
(Thermo Fisher Scientific). Images were obtained using an Axioskop 2 up-
right microscope with AxioVision software (using Carl Zeiss 40×/0.75NA 
Plan-Neofluar and 10×/0.25NA Achroplan for synaptophysin immunostaining 
in the CA3 region, and Carl Zeiss 10×/0.25NA Achroplan for EAAT2 
and A immunostaining in the hippocampal dentate gyrus region). In addi-
tion, omission of primary antibodies resulted in a lack of immunoreactivity. 
The images of synaptophysin and 6E10 immunoreactivity for synaptic integ-
rity and the A deposition, respectively, were analyzed with ImageJ 1.48b 
software. For quantification of synaptophysin immunoreactivity on the CA3a 
region (Figs. 3 E, 5 D, 6 D, and 7 D), five to six images (in an area of 222 × 
166 µm) from a series of sections for each mouse were collected. The signal 
intensities of these images were determined after subtracting background sig-
nals. The mean of these five to six signal intensities represents the mean signal 
intensity for each individual mouse. The number of animals used in each ex-
periment is indicated in the figure legend. The mean intensity of WT samples 
was arbitrarily set as 100%, and the other samples were normalized to WT 
samples. For quantification of 6E10 immunoreactivity on the hippocampal 
regions (Figs. 3 F, 5 E, 6 E, and 7 E), 12 images (in an area of 888 × 666 µm) 
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